Targeted metabolomic assessment of sub-lethal toxicity of halogenated acetic acids (HAAs) to *Daphnia magna*

Lisa M. Labine ^{1,2} and Myrna J. Simpson ^{1,2,*}

- ¹ Department of Chemistry University of Toronto, 80 St. George St., Toronto, ON, M5S 3H6
- ² Environmental NMR Centre and Department of Physical and Environmental Sciences, University of Toronto Scarborough, 1265 Military Trail, Toronto, ON, M1C 1A4.
- * Correspondence: myrna.simpson@utoronto.ca ; Tel.: +1-416-287-7234

1. Lethal concentration (LC50) determination for halogenated acetic acids (HAAs)

1.1. HAAs preparation for LC50 experiments

Concentrations of dichloroacetic acid (DCAA), trichloroacetic acid (TCAA), and dibromoacetic acid (DBAA) were confirmed before and after the lethal concentration (LC₅₀) test by sampling 30 mL aliquots from each concentration replicate. The aliquots were filtered through a 0.2 µm PTFE membrane filter (Target2, Thermo Scientific, Rockwood, TN) to remove algae from the samples. The filtered media was placed into 50 mL glass tubes with 12 g of sodium sulfate (Fisher Scientific, Fair Lawn, NJ; 99.8% purity) and then acidified with 2 mL of 18 M sulfuric acid (Fisher Scientific, Fair Lawn, NJ; < 95% purity). To the acidified media, 3 mL of methyl tert-butyl ether (MTBE; Alfa Aesar, Ward Hill, MA; 99% purity) was added. The tubes were then manually shaken for 1 min. For derivatization prior to gas chromatography (GC)-mass spectrometry (MS), the organic phase was removed and transferred into 10 mL vials where 1 mL of 10% (v/v) sulfuric acid solution in methanol (Fisher Scientific, Fair Lawn, NJ; 99.9% purity) was added. The samples were then heated to 50 °C for 2 h. The samples were then transferred to 20 mL vials and 4 mL of a 0.704 M sodium sulfate solution was added to remove any underivatized compounds from the organic phase. The organic phase was transferred into 2mL chromatography vials for analysis of the LC50 concentration of the halogenated acetic acids (HAAs).

1.1. Quantification of HAAs by gas chromatography – mass spectrometry (GC-MS)

Analysis of the LC₅₀ HAA concentrations was performed using gas chromatography (GC, Agilent Technologies, 7890B) hyphenated with a mass spectrometer (MS, Agilent Technologies, 5977B) using a previously published method [85]. The oven temperature was first held at 35 °C for 10 min followed by a ramping to 75 °C at a rate of 5 °C/min. The temperature was then held constant for 15 min, and then increased to 185 °C at a rate of 25 °C/min and held for one minute. The total temperature program lasted 38.4 min and all compounds were eluted within the first 20 min of the program. Details of the parameters used in the mass spectrometer are summarized in Table S1 and Table S2. The concentrations of the LC₅₀ exposure media were confirmed using the method above for DCAA, TCAA, and DBAA.

Table 1. Gas chromatography - mass spectrometry (GC-MS) parameters used for halogenated acetic acid (HAAs) detection.

| Parameter | Details |
|---------------------------|--|
| Carrier Gas | N_2 |
| Injection Temperature | 200 °C |
| Transfer Line Temperature | 280 °C |
| Split | 1:10 |
| Ionization | Electron Impact (EI) |
| Voltage | 70 eV |
| Column | HP-5MS (30m × 0.25mm (I.D.) × 0.25µm film thickness) |

| In | jection Volume | 3μ | ιL |
|----|----------------|----|----|

Table S2. Gas chromatography-mass spectrometry (GC-MS) HAA retention times.

| Compound | Retention Time (min) | Derivatized Compound |
|-----------------------------|----------------------|-------------------------|
| Dichloroacetic acid (DCAA) | 10.162 | Methyl dichloroacetate |
| Trichloroacetic acid (TCAA) | 15.057 | Methyl trichloroacetate |
| Dibromoacetic acid (DBAA) | 18.779 | Methyl dibromoacetate |

2. LC₅₀ reference toxicant (NaCl) sample preparation and analysis by ion chromatography (IC)

Concentration of the reference toxicant was also confirmed at the beginning and end of the LC₅₀ test, as such aliquots of 30 mL were taken from the exposure media both before and after the 48 h exposure. The aliquots were filtered through a 0.22 μ m PTFE membrane filter (Target2, Thermo Scientific, Rockwood, TN) to remove algae and particulate matter from the samples. The samples were then placed into 15 mL tubes and ion chromatography (IC) was used to determine the concentration of chloride anion in the samples to confirm the amount of NaCl (used as a reference during LC₅₀ measurements). Anion chromatography was performed using a Metroohm 930 compact IC flux. The chromatography mobile phase was water with 1 mM of NaHCO₃ and 3.2 mM of Na₂CO₃ and an ion regeneration solution of water with 100 mM of H₂SO₄. All standards and samples were diluted ten times before the analysis of the anions. The concentrations of the LC₅₀ exposure reference toxicant was confirmed using the concentration of chloride in the sample which was calibrated using a standard addition standard curve.

3. Daphnia exposure to halogenated acetic acids (HAAs)

3.1. HAAs sub-lethal exposure sample preparation

To confirm the nominal concentration of DCAA, TCAA, and DBAA in the exposure media, aliquots of 3 mL were sampled both before and after the 48 h sub-lethal exposure to *D. magna*. The aliquots were filtered through a 0.22 μ m PTFE membrane filter (Target2, Thermo Scientific, Rockwood, TN) to remove algae from the samples. The filtrate was then diluted using ultrapure (<18 M Ω) water so the concentrations of the samples would fall within the linear calibration range for each of the compounds. Once the samples were diluted, they were then transferred into 2 mL amber chromatography vials for analysis.

3.2. LC-MS/MS Analysis for confirming nominal exposure concentrations

3.2.1. Analysis of DCAA in Daphnia exposure media

DCAA concentration measurements were based on the method of Meng et al. [86]. The instrument used for analysis was an Agilent Technologies 1260 Infinity (Agilent Technologies, Mississauga, ON) hyphenated to an Agilent Technologies 6420A triple quadrupole MS (Agilent Technologies, Mississauga, ON). LC separation of DCAA was performed using a Waters Acquity BEH Cs (2.1 mm \times 100 mm \times 1.7 μ m) column (Waters Corporation; Milford, MA). The column compartment was maintained at 40 °C, and the binary pump operated at a flow rate of 0.225 mL/min. Samples of 10 µL were injected into the column for chromatographic separation which occurred using gradient elution composed of mobile phase A (water with 0.5% acetic acid (v/v)) and mobile phase B (acetonitrile with 0.1% acetic acid (v/v) beginning at a 95:5 solvent composition. The gradient then changed to a 60:40 (A: B) composition over 4 min. The program then increased composition of B to 100% over the next minute. The program was held at 100% B for one minute before returning to the initial composition of 95:5 over 1.5 min. The total program leads to a run time of 7.5 min, with a post equilibration time of 5 min after every sample run. The sample entered the MS where it was negatively ionized using electrospray ionization (ESI) with the source at a temperature of 350 °C and a gas flow rate of 8 L/min and a nebulizer pressure of 40 psi. The voltage of the discharge capillary is 3000 eV. The MS1 and MS2 temperatures were both maintained at 100 °C during the analysis. The

parameters for the fragmentation of the ions can be found in Table S3 along with the information for TCAA and DBAA.

3.2.2. Analysis of TCAA and DBAA in Daphnia exposure media

TCAA and DBAA concentration measurements were based on the method of Luo et al. [87]. The instrument used for analysis was an Agilent Technologies 1260 Infinity (Agilent Technologies, Mississauga, ON) hyphenated to an Agilent Technologies 6420A triple quadrupole MS (Agilent Technologies, Mississauga, ON). The LC separation of DCAA and DBAA was performed using a Waters Acquity BEH C8 (2.1 mm \times 100 mm \times 1.7 μ m) column (Milford, MA). Samples of 10 µL were injected into the column to undergo separation and analysis. The column compartment was maintained at 40 °C, and the binary pump operated at a flow rate of 0.225 mL/min. Chromatographic separation occurred using gradient elution composed of mobile phase A (water with 10mM ammonium formate) and mobile phase B (acetonitrile) beginning at a 40:60 solvent composition. The gradient then changed to a composition of 60:40 (A: B) over 1.5 min. The program then increased the percentage of mobile phase A to a composition of 75:25 (A:B) over 2.5 min. The solvent composition was then increased to 100% mobile phase A over 2 min. Over the next 1.5 min the composition changed to 95:5 (A:B). The total run time of each chromatographic separation was 5 min with a post-equilibration time of 2 min. The sample entered the mass spectrometer where it was negatively ionized using electrospray ionization (ESI) with the source chamber at a temperature of 350 °C, and the voltage of the discharge capillary set to 3000 eV. The gas flow rate was 8 L/min with a nebulizer pressure of 40 psi. During the analysis the temperature of the MS1 and MS2 were maintained at 100 °C. The parameters for the fragmentation of the ions can be found in Table S3 along with the information for DCAA.

| Compound | Precursor Ion (M-H ⁺) (<i>m</i> / <i>z</i>) | Fragmen- tor | Collision En- ergy | Product Ion (m/z) |
|--------------------------------|--|-----------------|-----------------------|----------------------|
| Dichloroacetic acid (DCAA) | 126.9 | 50 eV | 8 | 83.0 |
| Trichloroacetic acid (TCAA) | 160.9 | 110 eV | 5 | 116.9 |
| Dibromoacetic acid (DBAA) | 214.8 | 50 eV | 4 | 170.0 |

Table S3. Parameters for the detection of halogenated acetic acids (HAAs) using tandem mass spectrometry (MS/MS).

Table S4. Measured exposure concentrations and standard deviation for dichloroacetic acid (DCAA) following analysis using LC-MS/MS.

| | Dichloroacetic Acid (DCAA) | | | | |
|------------------------------|------------------------------------|------------------|--|--|--|
| Nominal Concentration (mg/L) | Measured DCAA Concentration (mg/L) | | | | |
| | 0 h | 48 h | | | |
| 5.16 | 5.78 ± 0.17 | 5.05 ± 0.06 | | | |
| 6.88 | 7.70 ± 0.06 | 6.89 ± 0.06 | | | |
| 10.32 | 11.65 ± 0.07 | 10.04 ± 0.08 | | | |
| 20.65 | 22.74 ± 0.07 | 21.64 ± 0.17 | | | |

Table S5. Measured exposure concentrations and standard deviation for trichloroacetic acid (TCAA) following analysis using LC-MS/MS.

| | Trichloroacetic acid (TCAA) | | |
|------------------------------|-----------------------------|--------------------|--|
| Nominal Concentration (mg/L) | Measured TCAA Cor | icentration (mg/L) | |
| | 0 h | 48 h | |
| 8.86 | 8.81 ± 1.26 | 8.94 ± 0.05 | |
| 11.81 | 11.62 ± 1.07 | 12.17 ± 0.68 | |

| 17.72 | 17.78 ± 1.10 | 17.45 ± 0.16 |
|-------|------------------|------------------|
| 35.43 | 35.06 ± 0.47 | 35.14 ± 2.24 |

Table S6. Measured exposure concentrations for dibromoacetic acid (DBAA) following analysis using LC-MS/MS.

| | Dibromoacetic acid (DBAA) Measured DBAA Concentration (mg/L) | | |
|--------------------------------|--|--|--|
| Nominal Concentration (mg/L) | | | |
| _ | 0 h | 48 h | |
| 7.45 | 7.38 ± 0.20 | 7.02 ± 0.08 | |
| 9.94 | 10.16 ± 0.42 | 8.72 ± 0.15 | |
| 14.91 | 15.39 ± 0.35 | 13.57 ± 0.37 | |
| 29.81 | 31.70 ± 0.44 | 28.54 ± 0.67 | |
| 7.45 9.94 14.91 29.81 | 7.38 ± 0.20 10.16 ± 0.42 15.39 ± 0.35 31.70 ± 0.44 | 7.02 ± 0.08 8.72 ± 0.15 13.57 ± 0.37 28.54 ± 0.67 | |

Table S7. Measured exposure concentrations for control groups following analysis using LC-MS/MS.

| Exposure | DCAA Concentration | TCAA Concentration | DBAA Concentration |
|----------------|--------------------|--------------------|---------------------------|
| Group | (µg/L) | (µg/L) | (µg/L) |
| Control – 0 h | nd ^a | ndª | ndª |
| Control – 48 h | ndª | 5.58 ± 7.50 | nda |

and = not detected.

| Metabolite | Class | Retention Time (min) | MRM ¹ | Internal Standard (ITSD) ² |
|---------------------|-----------------------|--|------------------------------|---------------------------------------|
| Dutroccina | Amino scid dorivativo | 0.845 | 89.0 > 68.5 | Clusino da |
| T utrescine | Ammo actu derivative | 0.045 | 89.0 > 72.0 | Gryenie-dz |
| Spermidine | Polvamine | 0.852 | 146.2 > 72.0 | Glycine-d ₂ |
| opermittine | roryunnite | 0.002 | 146.0 > 73.2 | |
| | | | 112.0 > 68.0 | |
| Histamine | Neurotransmitter | 0.883 | 112.0 > 83.2 | Glycine-d ₂ |
| | | | 112.0 > 95.1 | |
| Trimethylenediamine | Polyamine | 0.866 | 75.0 > 41.0 | Glycine-d ₂ |
| | 5 | | 75.0 > 58.2 | , , |
| Ornithine | Amino acid | 0.938 | 133.0 > 70.0 | Glycine-d ₂ |
| TT: /:1: | A · · · 1 | 0.002 | 133.0 > 116.1 | |
| Histidine | Amino acid | 0.993 | 156.1 > 110.1 | Glycine-d ₂ |
| Arginine | Amino acid | 1.002 | 175.1 > 70.2 | Glycine-d ₂ |
| Cystine Dimer | Amino acid derivative | 1.011 | 241.0 > 74.1 | Glycine-d ₂ |
| Glucose-6-phosphate | Saccharide derivative | 1.028 25 25 1.044 10 | 259.0 > 79.0 | Glycine-d ₂ |
| Carriera | Aminopoid | 1 044 | 259.0 > 96.9 | Classica d |
| Chusing | Amino acid | 1.044 | 106.1 > 60.2 | Glycine-d2 |
| Giycine | Amino acid | 1.043 | 124.1 > 74.1 | Glycine-d2 |
| Aspuriic uciu | Amino acid dorivotivo | 1.061 | 134.1 > 74.1 | Glycine-d2 |
| Clutomino | Amino acid | 1.007 | 399.0 > 230.0 | Chucino de |
| <u> </u> | Amino acid | 1.080 | 147.1 > 04.1 | Clusing de |
| Lysine | Amino aciu | 1.000 | 120.0 > 56.0 | Gryenie-d2 |
| Homoserine | Amino acid derivative | 1.081 | 120.0 > 50.0 | Glycine-d ₂ |
| Threonine | Amino acid | 1 091 | 120.0 > 74.2 120.1 > 74.2 | Clycine-da |
| ΔΙανίνο | Amino acid | 1.091 | 89.9 \> 57.0 | Clycine-da |
| 711111111 | Allino acia | 1.005 | 104.1 > 86.1 | Giyenie-dz |
| GABA | Neurotransmitter | 1.092 | 104.1 > 87.1 | Glycine-d ₂ |
| Glutamic acid | Amino acid | 1 099 | 148.1 > 84.1 | Glycine-d ₂ |
| | | 1.077 | 132.0 > 68.2 | |
| Hydroxyproline | Amino acid derivative | 1.109 | 132.0 > 86.1 | Glycine-d ₂ |
| | | | 265.0 > 122.0 | |
| Thiamine | Vitamin | 1.116 | 265.0 > 144.0 | Glycine-d ₂ |
| | | | 176.0 > 70.0 | |
| Citrulline | Amino acid | 1.126 | 176.0 > 113.0 | Glycine-d ₂ |
| | NT 1 11 | 1 001 | 324.0 > 97.0 | |
| CMP | Nucleoside | 1.201 | 324.0 > 112.0 | Acyclovir |

Table S8. Metabolite class, retention time, MRM, and associated internal standards.

| Metabolite | Class | Retention Time (min) | MRM ¹ | Internal Standard (ITSD) ² | |
|----------------|-----------------------|--|---------------------------------|---------------------------------------|---------------|
| A | | 1 001 | 189.2 > 84.2 | Charling d | |
| Acetyiiysine | Amino acid derivative | 1.221 | 189.2 > 129.1 | Glycine-d2 | |
| Comitino | Dolyamino | 1 001 | 162.0 > 60.2 | Chusing de | |
| Carnitine | Polyamine | 1.231 | 162.0 > 103.0 | Glycine-d2 | |
| Chaling | Marrieluen angittan | 1 224 | 104.0 > 58.0 | Charing d | |
| Cnotine | Neurotransmitter | Retention Time (min) 1.221 1.231 1.234 1.234 1.272 1.276 1.313 1.313 1.314 1.326 1.319 1.336 1.327 1.851 1.844 1.845 2.001 2.002 2.008 2.124 2.254 2.330 2.682 2.831 | 104.0 > 60.0 | Glycine-d2 | |
| Proline | Amino acid | 1.272 | 116.1 > 70.2 | Glycine-d ₂ | |
| | Nucleoside | 1.07(| 325.0 > 97.0 | Ain | |
| UMP | Nucleoside | 1.276 | 325.0 > 112.9 | Acyclovif | |
| Malia arid | Carbourdia acid | 1 010 | 133.0 > 70.9 | Mothianing d | |
| | Carboxylic acid | 1.515 | 133.0 > 114.8 | Methonine-d3 | |
| | Nucleoside | 1 214 | 348.0 > 136.0 | A gualarin | |
| Alvir | Nucleoside | 1.314 | 348.0 > 337.1 | Acyclovii | |
| Domannina | Nouvetreneraitter | 1 276 | 154.1 > 91.1 | Mothianing d | |
| Dopumine | Neurotransmitter | 1.526 | 154.1 > 137.0 | Methonine-d3 | |
| Valine | Amino acid | 1.319 | 118.1 > 72.0 | Methionine-d ₃ | |
| Methionine | Amino acid | 1.336 | 150.1 > 104.1 | Methionine-d ₃ | |
| Acatulahalina | Nourotropopittor | $\begin{array}{c c c c c c c c c c c c c c c c c c c $ | Neurotran amittar 1 227 146.1>6 | 146.1 > 60.1 | Mothianing d |
| Acergicnonne | Neurotransmitter | 1.327 | 146.1 > 87.0 | Methormie-d3 | |
| Nicotinic acid | Vitamin | $ \begin{array}{r} 1.326 \\ 1.319 \\ 1.336 \\ 1.327 \\ 1.327 \\ 1.327 \\ 1.851 \\ 1 \\ 1.851 \\ 1 \\ 1.844 \\ 1^{\prime} 1 1.844 \\ 1^{\prime} 1 1 1 $ | 124.1 > 78.1 | Mothiopipo de | |
| | vitallilli | 1.001 | 124.1 > 80.3 | Methormie-d3 | |
| Citric acid | Carboyalic acid | 1.234 1.272 1.276 1.313 1.314 1.326 1.319 1.336 1.327 1.851 1.844 1.845 1.845 2.001 2.002 2.008 2.124 2.330 | Carbourdia a rid 1.844 191.0 | 191.0 > 86.7 | Mathianina da |
| Curic uciu | Carboxylic aciu | 1.044 | 191.0 > 111.0 | Methormie-d3 | |
| CMP | Nucleoside | 1.276 1.313 1.314 1.326 1.319 1.326 1.319 1.336 1.327 1.851 1.844 1.845 1.845 2.001 2.002 2.008 2.124 2.254 | 364.0 > 97.2 | Agualovir | |
| Givir | Trucleoside | 1.045 | 364.0 > 152.0 | Acyclovii | |
| ΙλΙΡ | Nucleoside | 1.845 | 349.0 > 96.8 | Acyclovir | |
| 11111 | Trucleoside | Retention Time (min) 1.221 1.231 1.234 1.272 1.272 1.276 1.313 1.314 1.326 1.319 1.336 1.327 1.851 1.844 1.845 1.845 2.001 2.002 2.003 2.124 2.254 2.330 2.682 2.831 | 349.0 > 137.0 | Acyclovii | |
| Asparagine | Amino acid | 2.001 | 133.1 > 87.0 | Methionine-d ₃ | |
| Leucine | Amino acid | 2.002 | 132.1 > 86.2 | Methionine-d ₃ | |
| Hridina | Nucleoside | 2 008 | 245.0 > 109.4 | Acualovir | |
| Unume | Trucleoside | 2.000 | 245.0 > 113.0 | Acyclovii | |
| Isoleucine | Amino acid | 2.124 | 132.1 > 86.2 | Methionine-d ₃ | |
| Tyrosine | Amino acid | 2.254 | 182.1 > 165.0 | Methionine-d ₃ | |
| Turamina | Nucleoside | 2 220 | 138.0 > 93.1 | Mothiopino de | |
| 1 yrumine | Inucleoside | 1.234 1.272 1.276 1.313 1.314 1.314 1.326 1.319 1.336 1.327 1.851 1.851 1.844 1.845 2.001 2.002 2.008 2.124 2.254 2.330 2.682 2.831 | 2.330 138.0 > 121.0 | 138.0 > 121.0 | Methormie-d3 |
| Adonosino | Nucleosido | Retention Time (min) 1.221 1.231 1.234 1.272 1.276 1.313 1.314 1.326 1.319 1.336 1.327 1.851 1.845 1.845 2.001 2.002 2.003 2.124 2.254 2.330 2.682 2.831 | 268.0 > 57.0 | Acyclovir | |
| AuenOsine | | | 268.0 > 136.0 | Acyclovii | |
| Inocina | Nucleosido | 2 821 | 269.0 > 57.1 | Acuclostin | |
| 111051110 | inucleoside | 2.031 | 269.0 > 137.0 | ACYCIOVII | |

Table S8. Continued. Metabolite class, retention time, MRM, and associated internal standards.

| Metabolite | Class | Retention Time (min) | MRM ¹ | Internal Standard (ITSD) ² |
|---------------------------|---------------------|----------------------|------------------|---------------------------------------|
| Currenting | N | 2.000 | 284.0 > 134.5 | A |
| Guunosine | Nucleoside | 2.880 | 284.0 > 152.2 | Acyclovir |
| Phenylalanine | Amino acid | 3.269 | 166.1 > 120.1 | Phenyl-d₅-alanine |
| Tryptophan | Amino acid | 4.041 | 205.1 > 188.1 | Phenyl-d₅-alanine |
| Dileofferin | Vitania | 4 ()(| 377.0 > 243.0 | Dhourd d clouires |
| Kibojiuoin | Vitamin | 4.020 | 377.0 > 359.0 | Phenyi-d5-alanine |
| Cattidina | Nucleosido | 6 070 | 244.0 > 83.1 | A guelouir |
| Cyttuthe | Nucleoside | 0.070 | 244.0 > 97.0 | Acyclovir |
| Acyclovir | Nucleoside Analogue | 2.975 | 226.1 > 151.9 | ITSD |
| Glycine-d2 | Amino acid | 1.045 | 78.1 > 32.2 | ITSD |
| Methionine-d ₃ | Amino acid | 1.326 | 153.1 > 56.2 | ITSD |
| Phenyl-d5-alanine | Amino acid | 3.230 | 171.1 > 106.1 | ITSD |

Table S8. continued. Metabolite class, retention time, MRM, and associated internal standards.

¹Multiple reaction monitoring (MRM) in bold used for quantification, secondary MRM was used for qualitative confirmation of the metabolite. ²Internal standards used to ensure ionization efficiency of external standards and endogenous metabolites of *D. magna*.



Figure S1. Averaged (n = 12) principal component analysis (PCA) and partial least squares – discriminant analysis (PLS-DA) scores plots comparing variation in the metabolic profile across exposure groups to the control for components 1 and 2, and 3 and 4. Statistical significance (p < 0.05) is outlined by the presence of an asterisk (*). A) PCA PC 1 and PC 2 of DCAA exposure, B) PCA PC 3 and PC 4 of DCAA exposure, C) PLS-DA of DCAA exposure, D) PCA PC 1 and PC 2 of TCAA exposure, E) PCA PC 3 and PC 4 of TCAA exposure, F) PLS-DA of TCAA exposure, G) PCA PC 1 and PC 2 of DBAA exposure, H) PCA PC 3 and PC 4 of DBAA exposure, I) PLS-DA of DBAA exposure.



Figure S2. A) PLS-DA loadings figure demonstrates the variable importance in projection (VIP) and the relative concentration of the metabolites following DCAA exposure in each corresponding group of the study. Results demonstrated for the top 15 metabolites responsible for variance in the metabolome. **B)** ANOVA of metabolite concentrations, inosine (1) and guanosine (2), are statistically significant from the control group after exposure to DCAA (p < 0.05). Individual metabolite change figures can be found in Figure S4.



Figure S3. Analysis of averaged metabolite concentrations (n = 12) where 0 is the average metabolite concentrations across all treatment groups (DCAA exposure and the control). The colour gradient (blue to red) show the relative difference compared to the average metabolite concentration and correlated treatments and metabolites are linked on the upper x-axis and left y-axis respectively.



Figure S4. Averaged (n = 12) metabolite percent changes relative to the control. Statistical significance (p < 0.05) was determined with a two-tailed, equal variance *t*-test and is outlined with the presence of an asterisk (*).



Figure S5. Pearson correlation plot for DCAA exposure which demonstrates the correlation between metabolites measured in *D. magna* extract. Dark red, indicates a strong positive correlation and dark blue represents a strong negative correlation between the two given metabolites.



Figure S6. A) PLS-DA loadings figure demonstrates the variable importance in projection (VIP) and the relative concentration of the metabolites following TCAA exposure in each corresponding group of the study. Results demonstrated for the top 15 metabolites responsible for variance in the metabolome. B) ANOVA of metabolite concentrations, inosine (1) is statistically significant from the control group after exposure to TCAA (p < 0.05). Individual metabolite change figures can be found in Figure S8.



Figure S7. Analysis of averaged metabolite concentrations (n = 12) where 0 is the average metabolite concentrations across all treatment groups (TCAA exposure and the control). The colour gradient (blue to red) show the relative difference compared to the average metabolite concentration and correlated treatments and metabolites are linked on the upper x-axis and left y-axis respectively.



Figure S8. Averaged (n = 12) metabolite percent changes following sub-lethal exposure to TCAA relative to the control. Statistical significance (p < 0.05) was determined with a two-tailed, equal variance *t*-test and is outlined with the presence of an asterisk (*).

Methionine

Isoleucine

Inosine

Cytidine

88° 181 112

So. A

60

50

100

-1500

-200

-400

-600

-200

-400

-800



Figure S9. Pearson correlation plot for TCAA exposure which demonstrates the correlation between metabolites measured in *D. magna* extract. Dark red, indicates a strong positive correlation and dark blue represents a strong negative correlation between the two given metabolites.



Figure S10. A) PLS-DA loadings figure demonstrates the variable importance in projection (VIP) and the relative concentration of the metabolites following DBAA exposure in each corresponding group of the study. Results demonstrated for the top 15 metabolites responsible for variance in the metabolome. B) ANOVA of metabolite concentrations, adenosine (1), inosine (2), and guanosine (3) is statistically significant from the control group after exposure to DBAA (p < 0.05). Individual metabolite change figures can be found in Figure S12.



Figure S11. Analysis of averaged metabolite concentrations (n = 12) where 0 is the average metabolite concentrations across all treatment groups (DBAA exposure and the control). The colour gradient (blue to red) show the relative difference compared to the average metabolite concentration and correlated treatments and metabolites are linked on the upper x-axis and left y-axis respectively.



Figure S12. Averaged (n = 12) metabolite percent change following sub-lethal exposure to DBAA relative to the control. Statistical significance (p < 0.05) was determined with a two-tailed, equal variance *t*-test and is outlined with the presence of an asterisk (*).



Figure S13. Pearson correlation plot for TCAA exposure which demonstrates the correlation between metabolites measured in *D. magna* extract. Dark red, indicates a strong positive correlation and dark blue represents a strong negative correlation between the two given metabolites.



Figure S14. MetaboAnalyst pathway analysis for sub-lethal exposure of *D. magna* to DCAA at 20.65 mg/L. Statistical significance (p < 0.10) denoted asterisk (*); (A) Citrate Cycle (TCA cycle), (B) Purine metabolism.



Figure S15. MetaboAnalyst pathway analysis for sub-lethal exposure of *D. magna* to TCAA at 8.86 mg/L. Statistical significance (p < 0.10) denoted by asterisk (*). Impacted pathways listed in Table 2 in main article.



Figure S16. MetaboAnalyst pathway analysis for sub-lethal exposure of *D. magna* to DBAA at 7.45 mg/L. Statistical significance (p < 0.10) denoted by asterisk (*); (A) Thiamine metabolism, (B) Tyrosine metabolism, (C) Citrate cycle (TCA cycle).



Figure S17. MetaboAnalyst pathway analysis for sub-lethal exposure of *D. magna* to DBAA at 7.45 mg/L. Statistical significance (p < 0.10) denoted by asterisk (*); (A) Purine metabolism.

References

- 85. Xie, Y. Analyzing Haloacetic Acids Using Gas Chromatography/Mass Spectrometry. *Water Res.* 2001, 35, 1599–1602, doi:10.1016/S0043-1354(00)00397-3.
- 86. Meng, L.; Wu, S.; Ma, F.; Jia, A.; Hu, J. Trace determination of nine haloacetic acids in drinking water by liquid chromatography– electrospray tandem mass spectrometry. *J. Chromatogr. A* **2010**, *1217*, 4873–4876, doi:10.1016/J.CHROMA.2010.04.074.
- 87. Luo, Q.; Wang, D.; Wei, Z.; Wang, Z. Optimized chromatographic conditions for separation of halogenated acetic acids by ultraperformance liquid chromatography-electrospray ionization-mass spectrometry. *J. Chromatogr. A* 2013, 1277, 26–34, doi:10.1016/j.chroma.2012.12.046.